FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8150人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839801, encodeId=88fa1839801e1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准帕金森病新药上市，显著缩短“关闭期”时间, objectType=article, longId=193123, objectId=7ab21931233b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ab21931233b, replyNumber=0, likeNumber=96, createdTime=2020-12-14, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ab21931233b, moduleTitle=美国FDA批准帕金森病新药上市，显著缩短“关闭期”时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ab21931233b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839694, encodeId=b5ad1839694c5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=礼来的CGRP抑制剂Emgality喜获FDA批准，成为阵发性丛集性头痛的治疗药物, objectType=article, longId=167749, objectId=2b1416e7498d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b1416e7498d, replyNumber=0, likeNumber=64, createdTime=2019-11-13, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b1416e7498d, moduleTitle=礼来的CGRP抑制剂Emgality喜获FDA批准，成为阵发性丛集性头痛的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b1416e7498d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Esperion的ATP柠檬酸裂解酶抑制剂Nexletol，获FDA批准治疗心血管疾病, objectType=article, longId=188793, objectId=83f0188e9391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83f0188e9391, replyNumber=0, likeNumber=61, createdTime=2020-06-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83f0188e9391, moduleTitle=Esperion的ATP柠檬酸裂解酶抑制剂Nexletol，获FDA批准治疗心血管疾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83f0188e9391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839715, encodeId=b9911839e15d4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=创伤性脑损伤的治疗：FDA批准了MR-301的研究性新药申请, objectType=article, longId=178355, objectId=7d8d1e835594, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d8d1e835594, replyNumber=0, likeNumber=81, createdTime=2020-01-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d8d1e835594, moduleTitle=创伤性脑损伤的治疗：FDA批准了MR-301的研究性新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d8d1e835594)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839712, encodeId=34331839e1265, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化, objectType=article, longId=177980, objectId=fe551e798093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe551e798093, replyNumber=0, likeNumber=83, createdTime=2020-06-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe551e798093, moduleTitle=FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe551e798093)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839718, encodeId=f4811839e1853, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌, objectType=article, longId=179672, objectId=33491e967221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33491e967221, replyNumber=0, likeNumber=68, createdTime=2019-11-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33491e967221, moduleTitle=强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33491e967221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839713, encodeId=7f131839e13aa, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎, objectType=article, longId=178241, objectId=2a911e824102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a911e824102, replyNumber=0, likeNumber=69, createdTime=2020-07-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a911e824102, moduleTitle=礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a911e824102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839695, encodeId=7f39183969586, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准GSK的哮喘药物Nucala新的给药方式，患者只需每四周服用一次, objectType=article, longId=167846, objectId=827c16e846d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=827c16e846d7, replyNumber=0, likeNumber=68, createdTime=2019-10-05, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=827c16e846d7, moduleTitle=FDA批准GSK的哮喘药物Nucala新的给药方式，患者只需每四周服用一次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=827c16e846d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839757, encodeId=2e891839e57cc, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌，获得FDA批准, objectType=article, longId=185039, objectId=2317185039ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2317185039ae, replyNumber=0, likeNumber=53, createdTime=2020-01-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2317185039ae, moduleTitle=Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2317185039ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839683, encodeId=1ccc183968314, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准**登革热疫苗，可在首次感染后注射, objectType=article, longId=165611, objectId=5224165611e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5224165611e0, replyNumber=0, likeNumber=64, createdTime=2019-10-27, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5224165611e0, moduleTitle=美国FDA批准**登革热疫苗，可在首次感染后注射, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5224165611e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839773, encodeId=aa431839e7356, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准RV001治疗晚期前列腺癌的IIb期临床试验, objectType=article, longId=189089, objectId=994d1890897b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=994d1890897b, replyNumber=0, likeNumber=70, createdTime=2020-08-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=994d1890897b, moduleTitle=美国FDA批准RV001治疗晚期前列腺癌的IIb期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=994d1890897b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839786, encodeId=43101839e8626, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准罗氏的Actemra COVID-19试验, objectType=article, longId=190985, objectId=ad8619098568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad8619098568, replyNumber=0, likeNumber=80, createdTime=2020-04-08, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad8619098568, moduleTitle=FDA批准罗氏的Actemra COVID-19试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad8619098568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839784, encodeId=315b1839e84ac, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准新冠病毒COVID-19的快速检测试剂盒--45分即可确认是否感染, objectType=article, longId=190792, objectId=e405190e9221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e405190e9221, replyNumber=0, likeNumber=58, createdTime=2020-10-25, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e405190e9221, moduleTitle=FDA批准新冠病毒COVID-19的快速检测试剂盒--45分即可确认是否感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e405190e9221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839758, encodeId=d0a91839e5857, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准CGRP抑制剂Ubrelvy治疗急性偏头痛, objectType=article, longId=185147, objectId=e71018514e6b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e71018514e6b, replyNumber=0, likeNumber=68, createdTime=2020-03-18, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e71018514e6b, moduleTitle=美国FDA批准CGRP抑制剂Ubrelvy治疗急性偏头痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e71018514e6b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839728, encodeId=cead1839e284d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准礼来公司的Reyvow用于成人偏头痛的急性治疗, objectType=article, longId=181057, objectId=467418105e92, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=467418105e92, replyNumber=0, likeNumber=58, createdTime=2020-07-12, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=467418105e92, moduleTitle=FDA批准礼来公司的Reyvow用于成人偏头痛的急性治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=467418105e92)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839750, encodeId=d62a1839e50fc, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=184290, objectId=431b184290f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431b184290f9, replyNumber=0, likeNumber=68, createdTime=2020-09-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431b184290f9, moduleTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431b184290f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839716, encodeId=0fde1839e16c3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病, objectType=article, longId=179152, objectId=816f1e9152ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=816f1e9152ed, replyNumber=0, likeNumber=78, createdTime=2019-10-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=816f1e9152ed, moduleTitle=FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=816f1e9152ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839761, encodeId=50cf1839e6153, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准PARP抑制剂Lynparza用于胰腺癌的维持治疗, objectType=article, longId=185523, objectId=1ffa1855237e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ffa1855237e, replyNumber=0, likeNumber=56, createdTime=2020-03-05, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ffa1855237e, moduleTitle=FDA批准PARP抑制剂Lynparza用于胰腺癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ffa1855237e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839777, encodeId=0fc41839e77ee, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=在弓形虫病药物Daraprim价格上涨5000%后，FDA批准了其仿制药上市, objectType=article, longId=189494, objectId=e7f118949412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7f118949412, replyNumber=0, likeNumber=76, createdTime=2020-03-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7f118949412, moduleTitle=在弓形虫病药物Daraprim价格上涨5000%后，FDA批准了其仿制药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7f118949412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839760, encodeId=7d3c1839e6079, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准抗CTLA-4抗体ONC-392的IDN, objectType=article, longId=185514, objectId=40ed18551441, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ed18551441, replyNumber=0, likeNumber=65, createdTime=2020-04-22, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ed18551441, moduleTitle=FDA批准抗CTLA-4抗体ONC-392的IDN, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ed18551441)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准帕金森病新药上市，显著缩短“关闭期”时间

2020-12-14

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

礼来的CGRP抑制剂Emgality喜获FDA批准，成为阵发性丛集性头痛的治疗药物

2019-11-13

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Esperion的ATP柠檬酸裂解酶抑制剂Nexletol，获FDA批准治疗心血管疾病

2020-06-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

创伤性脑损伤的治疗：FDA批准了MR-301的研究性新药申请

2020-01-21

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化

2020-06-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌

2019-11-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎

2020-07-24

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准GSK的哮喘药物Nucala新的给药方式，患者只需每四周服用一次

2019-10-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌，获得FDA批准

2020-01-27

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准**登革热疫苗，可在首次感染后注射

2019-10-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准RV001治疗晚期前列腺癌的IIb期临床试验

2020-08-01

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准罗氏的Actemra COVID-19试验

2020-04-08

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准新冠病毒COVID-19的快速检测试剂盒--45分即可确认是否感染

2020-10-25

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准CGRP抑制剂Ubrelvy治疗急性偏头痛

2020-03-18

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准礼来公司的Reyvow用于成人偏头痛的急性治疗

2020-07-12

bugit (审核中...)

前往app查看评论内容

#FDA批准#

罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌

2020-09-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病

2019-10-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准PARP抑制剂Lynparza用于胰腺癌的维持治疗

2020-03-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

在弓形虫病药物Daraprim价格上涨5000%后，FDA批准了其仿制药上市

2020-03-23

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准抗CTLA-4抗体ONC-392的IDN

2020-04-22

科室
- - 订阅+
  - 更多科室
工具
服务